| Literature DB >> 27383665 |
Franco Scinicariello1, Melanie C Buser.
Abstract
BACKGROUND: Exposure to environmental phenols (e.g., bisphenol A, benzophenone-3, and triclosan) and parabens is widespread in the population. Many of these chemicals have been shown to have anti-androgenic effects both in vitro and in vivo.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27383665 PMCID: PMC5132630 DOI: 10.1289/EHP150
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Weighted characteristics for children and adolescent (6–19 years) participants in NHANES 2011–2012.
| Characteristic | Male children | Male adolescents | Female children | Female adolescents |
|---|---|---|---|---|
| Urinary bisphenol A (ng/mL) [GM (SE)] | 1.74 (0.26) | 1.94 (0.29) | 1.40 (0.17) | 1.49 (0.21) |
| Urinary benzophenone-3 (ng/mL) [GM (SE)] | 15.57 (4.61) | 20.03 (5.69) | 18.31 (3.96) | 35.59 (14.40) |
| Urinary triclosan (ng/mL) [GM (SE)] | 8.79 (1.80) | 8.55 (1.67) | 6.30 (0.72) | 12.27 (3.05) |
| Urinary total parabens (ng/mL) [GM (SE)] | 15.07 (4.19) | 18.51 (4.15) | 29.51 (6.58) | 63.75 (17.23) |
| Age (years) [GM (SE)] | 8.39 (0.20) | 15.50 (0.19) | 8.76 (0.15) | 15.20 (0.17) |
| Serum total testosterone (ng/dL) [GM (SE)] | 3.75 (0.60) | 276.07 (27.71) | 5.80 (0.54) | 22.78 (0.73) |
| Serum cotinine (ng/mL) [GM (SE)] | 0.06 (0.01) | 0.12 (0.02) | 0.05 (0.01) | 0.14 (0.05) |
| Urinary creatinine (mg/dL) [GM (SE)] | 71.18 (6.16) | 112.65 (10.23) | 68.09 (5.42) | 98.87 (11.42) |
| Total cholesterol (mg/dL) [GM (SE)] | 156.25 (2.27) | 148.93 (2.61) | 156.42 (3.33) | 159.16 (5.82) |
| Ratio family income to poverty [GM (SE)] | 1.65 (0.09) | 1.73 (0.25) | 1.76 (0.18) | 1.73 (0.22) |
| Obesity | ||||
| Normal/underweight [% (SE)] | 93.83 (1.93) | 59.12 (3.11) | 86.16 (3.16) | 64.21 (8.17) |
| Overweight [% (SE)] | 5.14 (2.31) | 23.40 (3.64) | 9.07 (3.85) | 16.25 (4.16) |
| Obese [% (SE)] | 1.03 (0.77) | 17.49 (4.58) | 4.78 (1.85) | 19.54 (6.14) |
| Race/ethnicity | ||||
| White (non-Hispanic) [% (SE)] | 54.45 (5.59) | 55.06 (4.75) | 55.13 (7.84) | 55.46 (6.60) |
| Non-Hispanic black [% (SE)] | 15.40 (1.97) | 15.73 (4.07) | 12.21 (3.17) | 15.44 (5.05) |
| Hispanic [% (SE)] | 21.78 (5.12) | 22.21 (3.98) | 25.10 (5.25) | 21.69 (4.07) |
| Other [% (SE)] | 7.37 (2.49) | 7.00 (2.45) | 7.57 (2.12) | 7.41 (1.44) |
| Session time of venipuncture | ||||
| Morning | 42.20 (5.42) | 51.94 (6.77) | 53.74 (4.01) | 42.36 (4.89) |
| Afternoon | 31.88 (3.96) | 29.45 (4.98) | 30.16 (4.51) | 36.83 (4.64) |
| Evening | 25.92 (4.75) | 18.61 (5.37) | 16.10 (3.06) | 20.81 (5.11) |
| Six month time period when the examination was performed | ||||
| 1 November through 30 April [% (SE)] | 52.60 (7.30) | 47.64 (9.29) | 48.08 (6.93) | 40.15 (7.91) |
| 1 May through 31 October [% (SE)] | 47.40 (7.30) | 52.36 (9.29) | 51.92 (6.93) | 59.85 (7.91) |
| Physical activity | ||||
| Yes [% (SE)] | 90.23 (3.05) | 71.43 (4.21) | ||
| No [% (SE)] | 9.77 (3.05) | 28.57 (4.21) | ||
Percent differences (95% CI) in serum total testosterone by quartiles of BP-3 exposure, National Health and Nutrition Examination Survey, 2011–2012.
| BP-3 exposure | Model 1 | Model 2 |
|---|---|---|
| Male children | ||
| Q1: ≤ 3.5 ng/mL | Reference | Reference |
| Q2: 3.6–8.8 ng/mL | –1.98 (–51.81, 97.39) | 7.25 (–46.74, 115.98) |
| Q3: 8.9–71.1 ng/mL | 27.12 (–20.55, 105.44) | 31.00 (–25.17, 129.33) |
| Q4: > 71.7 ng/mL | –1.98 (–44.57, 73.33) | 4.08 (–40.55, 82.21) |
| 0.53 | 0.70 | |
| Male adolescents | ||
| Q1: ≤ 4.0 ng/mL | Reference | Reference |
| Q2: 4.1–15.9 ng/mL | –7.69 (–43.45, 50.68) | 1.01 (–34.30, 55.27) |
| Q3: 16.0–48.7 ng/mL | –38.74 (–58.52, –10.42) | –32.97 (–54.16, –1.98) |
| Q4: > 48.7 ng/mL | –36.87 (–59.34, –1.98) | –32.97 (–54.16, –0.50) |
| 0.01 | 0.04 | |
| Female children | ||
| Q1: ≤ 6.6 ng/mL | Reference | Reference |
| Q2: 6.7–13.9 ng/mL | 10.52 (–19.75, 50.68) | 7.25 (–31.61, 68.20) |
| Q3: 14.0–58.5 ng/mL | 5.13 (–20.55, 39.10) | –0.50 (–50.84, 101.38) |
| Q4: > 58.6 ng/mL | 20.92 (–28.82, 105.44) | 10.52 (–68.65, 293.54) |
| 0.87 | 0.91 | |
| Female adolescents | ||
| Q1: ≤ 8.6 ng/mL | Reference | Reference |
| Q2: 8.7–23.7 ng/mL | 20.92 (3.05, 43.33) | 17.35 (–1.00, 39.10) |
| Q3: 23.8–164.0 ng/mL | 10.52 (–18.13, 49.18) | 12.75 (–16.47, 50.68) |
| Q4: > 164.0 ng/mL | 11.63 (–23.66, 64.87) | 16.18 (–21.34, 71.60) |
| 0.14 | 0.27 | |
Percent differences (95% CI) in serum total testosterone by quartiles of BPA exposure, National Health and Nutrition Examination Survey, 2011–2012.
| BPA exposure | Model 1 | Model 2 |
|---|---|---|
| Male children | ||
| Q1: ≤ 0.8 ng/mL | Reference | Reference |
| Q2: 0.9–1.5 ng/mL | 16.18 (–44.01, 141.09) | 9.42 (–46.74, 124.79) |
| Q3: 1.6–3.3 ng/mL | –14.79 (–62.84, 95.42) | –18.94 (–66.38, 93.48) |
| Q4: > 3.3 ng/mL | –10.42 (–41.14, 37.71) | –22.12 (–55.07, 34.99) |
| 0.27 | 0.19 | |
| Male adolescents | ||
| Q1: ≤ 0.9 ng/mL | Reference | Reference |
| Q2: 1.0–2.0 ng/mL | –49.34 (–70.18, –13.06) | –50.84 (–71.92, –13.93) |
| Q3: 2.1–3.7 ng/mL | –36.87 (–62.47, 6.18) | –38.12 (–63.21, 4.08) |
| Q4: > 3.7 ng/mL | –53.70 (–70.77, –26.66) | –52.29 (–71.35, –20.55) |
| 0.01 | 0.02 | |
| Female children | ||
| Q1: ≤ 0.7 ng/mL | Reference | Reference |
| Q2: 0.8–1.4 ng/mL | 8.33 (–28.82, 64.87) | 18.53 (–36.24, 118.15) |
| Q3: 1.5–2.8 ng/mL | 8.33 (–30.93, 69.89) | 19.72 (–42.88, 153.45) |
| Q4: > 2.8 ng/ mL | 20.92 (–35.60, 127.05) | 40.49 (–56.83, 352.67) |
| 0.86 | 0.94 | |
| Female adolescents | ||
| Q1: ≤ 0.7 ng/mL | Reference | Reference |
| Q2: 0.8–1.5 ng/mL | 24.61 (–7.69, 69.89) | 27.21 (–4.88, 71.60) |
| Q3: 1.6–3.2 ng/mL | 39.10 (–4.88, 103.40) | 36.34 (–6.76, 101.38) |
| Q4: > 3.2 ng/mL | 53.73 (9.42, 113.83) | 53.73 (12.75, 109.59) |
| 0.01 | < 0.01 | |
Percent differences (95% CI) in serum total testosterone by quartiles of TCS exposure, National Health and Nutrition Examination Survey, 2011–2012.
| TCS exposure | Model 1 | Model 2 |
|---|---|---|
| Male children | ||
| Q1: ≤ 2.5 ng/mL | Reference | Reference |
| Q2: 2.6–6.1 ng/mL | –34.95 (–72.47, 53.73) | –37.50 (–72.75, 41.91) |
| Q3: 6.2–18.1 ng/mL | –15.63 (–63.58, 93.48) | –17.30 (–62.09, 80.40) |
| Q4: > 8.1 ng/mL | –10.42 (–52.29, 158.57) | –16.18 (–51.32, 177.32) |
| 0.02 | 0.01 | |
| Male adolescents | ||
| Q1: ≤ 2.6 ng/mL | Reference | Reference |
| Q2: 2.7–5.7 ng/mL | –32.97 (–63.94, 23.37) | –24.42 (–55.51, 28.40) |
| Q3: 5.8–19.0 ng/mL | –39.95 (–61.71, –5.82) | –36.87 (–60.94, 2.02) |
| Q4: > 19.0 ng/mL | –10.42 (–41.73, 39.10) | –9.52 (–39.35, 33.64) |
| 0.04 | 0.08 | |
| Female children | ||
| Q1: ≤ 2.3 ng/mL | Reference | Reference |
| Q2: 2.4–3.9 ng/mL | –11.31 (–28.82, 11.63) | 22.14 (–34.30, 2.02) |
| Q3: 4.0–15.3 ng/mL | –32.97 (–52.29, –4.88) | –35.60 (–58.10, –1.00) |
| Q4: > 15.3 ng/ mL | –9.52 (–36.87, 28.40) | –17.30 (–56.83, 60.00) |
| 0.11 | 0.06 | |
| Female adolescents | ||
| Q1: ≤ 2.5 ng/mL | Reference | Reference |
| Q2: 2.6–7.3 ng/mL | –2.96 (–24.42, 24.61) | –3.92 (–27.39, 25.86) |
| Q3: 7.4–31.6 ng/mL | –4.88 (–30.93, 32.31) | –12.19 (–37.50, 24.61) |
| Q4: > 31.6 ng/mL | –11.31 (–34.30, 20.92) | –10.42 (–34.30, 22.14) |
| 0.69 | 0.88 | |
Percent differences (95% CI) in serum total testosterone by quartiles of ∑PAR exposure, National Health and Nutrition Examination Survey, 2011–2012.
| ∑PAR exposure | Model 1 | Model 2 |
|---|---|---|
| Male children | ||
| Q1: ≤ 4.4 ng/mL | Reference | Reference |
| Q2: 4.5–10.1 ng/mL | 44.77 (–21.34, 169.12) | 43.33 (–17.30, 148.43) |
| Q3: 10.2–40.0 ng/mL | –15.63 (–46.74, 32.31) | –14.79 (–42.88, 28.40) |
| Q4: > 40.0 ng/mL | 10.52 (–37.50, 95.42) | 16.18 (–36.24, 113.83) |
| 0.22 | 0.29 | |
| Male adolescents | ||
| Q1: ≤ 4.9 ng/mL | Reference | Reference |
| Q2: 5.0–10.2 ng/mL | –22.12 (–55.96, 39.10) | –13.06 (–51.36, 53.73) |
| Q3: 10.3–61.5 ng/mL | –16.47 (–45.66, 27.12) | –3.92 (–32.29, 36.34) |
| Q4: > 61.5 ng/mL | –23.66 (–51.32, 18.53) | –14.79 (–48.31, 41.91) |
| 0.49 | 0.82 | |
| Female children | ||
| Q1: ≤ 11.3 ng/mL | Reference | Reference |
| Q2: 11.4–22.7 ng/mL | 13.88 (–12.19, 47.70) | 19.72 (–12.19, 63.23) |
| Q3: 22.8–76.8 ng/mL | 12.55 (–21.34, 50.68) | 18.53 (–13.06, 63.23) |
| Q4: > 76.8 ng/ mL | 31.00 (–4.88, 82.21) | 53.73 (–18.13, 191.54) |
| 0.39 | 0.11 | |
| Female adolescents | ||
| Q1: ≤ 15.5 ng/mL | Reference | Reference |
| Q2: 15.6–66.6 ng/mL | –8.61 (–34.95, 29.69) | –5.82 (–32.29, 31.00) |
| Q3: 66.7–297.9 ng/mL | –21.34 (–43.45, 8.33) | –24.42 (–44.57, 3.05) |
| Q4: > 297.9 ng/mL | 3.05 (–29.53, 52.20) | 4.08 (–25.92, 47.70) |
| 0.11 | 0.02 | |